Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Lovastatin in Severe Persistent Asthma

Phase 1

Withdrawn

Conditions: Severe Persistent Asthma

Interventions: Drug: Placebo
Drug: Lovastatin

First Posted Date: 2008-06-04

Last Posted Date: 2013-06-21

Lead Sponsor: University of Chicago

Registration Number: NCT00689806

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia
Lymphoid Leukemia
Chronic Myelogenous Leukemia
Malignant Lymphoma
Hodgkin's Disease
Chronic Lymphocytic Leukemia
Myeloproliferative Disorder
Anemia, Aplastic
Myelodysplastic Syndromes

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Stem cells
Drug: Campath

First Posted Date: 2008-05-23

Last Posted Date: 2016-11-22

Lead Sponsor: University of Chicago

Target Recruit Count: 204

Registration Number: NCT00683046

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Rapamycin Plus Bevacizumab in Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancer
Metastatic Cancer

Interventions: Drug: Rapamycin (liquid)
Drug: Bevacizumab
Drug: Rapamycin (Tablets)

First Posted Date: 2008-04-28

Last Posted Date: 2014-01-17

Lead Sponsor: University of Chicago

Target Recruit Count: 28

Registration Number: NCT00667485

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Psychotherapy for Intermittent Explosive Disorder

Not Applicable

Completed

Conditions: Anger
Intermittent Explosive Disorder

Interventions: Behavioral: Cognitive Behavioral Therapy
Behavioral: Supportive Psychotherapy

First Posted Date: 2008-04-28

Last Posted Date: 2024-08-19

Lead Sponsor: University of Chicago

Target Recruit Count: 44

Registration Number: NCT00667212

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

Phase 4

Completed

Conditions: Contraception

Interventions: Device: Levonorgestrel-releasing intrauterine device (LNG-IUS)
Device: Copper T380A intrauterine device (CuT380A)

First Posted Date: 2008-04-04

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 23

Registration Number: NCT00653159

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Acceptability of the NuvaRing Among Students

Phase 4

Completed

Conditions: Birth Control Compliance

Interventions: Device: NuvaRing
Drug: Ortho Tri-cyclen Lo

First Posted Date: 2008-03-13

Last Posted Date: 2021-02-03

Lead Sponsor: University of Chicago

Target Recruit Count: 273

Registration Number: NCT00635570

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
University of Chicago, Section of Family Planning, Chicago, Illinois, United States

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

Not Applicable

Terminated

Conditions: Healthy

Interventions: Device: Levonorgestrel-releasing intrauterine system (LNG-IUS)

First Posted Date: 2008-03-13

Last Posted Date: 2023-03-22

Lead Sponsor: University of Chicago

Target Recruit Count: 42

Registration Number: NCT00635362

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Intranasal CO2 for Allergic Rhinitis

Not Applicable

Completed

Conditions: Allergic Rhinitis

Interventions: Other: Placebo
Device: Carbon dioxide, USP

First Posted Date: 2008-02-20

Last Posted Date: 2014-01-27

Lead Sponsor: University of Chicago

Target Recruit Count: 13

Registration Number: NCT00618410

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Not Applicable

Terminated

Conditions: Esophageal Cancer

Interventions: Drug: sorafenib

First Posted Date: 2008-02-20

Last Posted Date: 2014-03-12

Lead Sponsor: University of Chicago

Target Recruit Count: 3

Registration Number: NCT00619242

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?

Not Applicable

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: mometasone furoate nasal spray
Drug: placebo

First Posted Date: 2008-02-20

Last Posted Date: 2014-02-14

Lead Sponsor: University of Chicago

Target Recruit Count: 40

Registration Number: NCT00618332

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy